Quest Laboratories Ltd

Quest Laboratories Ltd IPO

IPO Price Range: ₹93 - 97

Quest Laboratories Limited is engaged in the business of manufacturing of pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. These formulations fall under the trademark Quest Laboratories Limited. The company produces a variety of products, comprising ethical drugs, generic drugs, and overthe-counter drugs (OTC). These products are available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids. This comprehensive approach allows the Company to address a wide range of medical needs and preferences among patients.

Min Investment

₹1,16,400

IPO Size

₹43 Cr

IPO Status

Closed

Quantity in 1 Lot

1200

Max Bid allowed

1

Listing Exchange

NSE

IPO Application Timeline of Quest Laboratories Ltd

Open Date15 May 2024
Close Date17 May 2024
Allotment Date21 May 2024
Listing Date23 May 2024

Key Statistics

Bid Opening DateBid Opening Date15 May 2024
Bid Closing DateBid Closing Date17 May 2024
Allotment DateAllotment Date21 May 2024
Issue SizeIssue Size₹43.16Cr
Quantity in 1 lotQuantity in 1 lot1200

Strength and risks

Strength

Strength

  • Multi-product capability.

  • Revenue from Government institutions.

  • Product Portfolio.

  • Research and Development.

  • Quality assurance.

  • Experienced Promoter and management team.

  • Supply Chain Efficiency.


Risk

Risk

  • The company has certain outstanding litigation against it, an adverse outcome of which may adversely affect its business, reputation and results of operations.

  • Any manufacturing or quality control problems may disrupt its business operations, damage the company reputation for high quality production and expose it to potential litigation or other liabilities, which would negatively impact its business, prospects, cash flows, results of operations and financial condition.

  • The Company is reliant on the demand from the pharmaceutical industry for a significant portion of its revenue. Any downturn in the pharmaceutical industry or an inability to increase or effectively manage its sales could have an adverse impact on the Companys business and results of operations.

  • The products that the company commercialize may not perform as expected which could adversely affect its business, financial condition and results of operations.

  • Any manufacturing or quality control problems may damage its reputation for high quality products and expose the company to litigation or other liabilities, which could adversely affect its financial results.

  • The availability of counterfeit drugs, such as drugs passed off by others as its products, could adversely affect the company goodwill and results of operations.

  • Its business is dependent and will continue to depend on the companys manufacturing facility, and the company is subject to certain risks in its manufacturing process. Any slowdown or shutdown in the company manufacturing operations or strikes, work stoppages or increased wage demands by its employees that could interfere with the company operations could have an adverse effect on its business, financial condition and results of operations.

  • Its existing manufacturing facility are concentrated in a single region i.e., Pithampur, Indore, Madhya Pradesh and the inability to operate and grow its business in this particular region may have an adverse effect on the company business, financial condition, results of operations, cash flows and future business prospects.

  • The company highly depends on its major raw materials on many of the suppliers who help it procure the same. The Company has not entered into long-term agreements with its suppliers for supply of raw materials. In the event the company is unable to procure adequate amounts of raw materials, at competitive prices its business, results of operations and financial condition may be adversely affected.

  • Too much concentration of its Business is from sale to government which may impact the companys Business.

Promoters Holding

Investors Holdings %
Anil Kumar Sabarwal85.17%
Tejaswini Sabarwal3.41%

About Quest Laboratories Ltd

OrganisationQuest Laboratories Ltd
HeadquartersDhar
IndustryPharmaceuticals

Frequently Asked Questions

  • What is the size of the Quest Laboratories Ltd IPO?

    The size of the Quest Laboratories Ltd IPO is ₹43.16Cr .

  • What is 'pre-apply' for Quest Laboratories Ltd IPO?

    'Pre-apply' for Quest Laboratories Ltd IPO indicates your interest in the IPO before it opens for subscription. This ensures quick application when the IPO goes live.

  • When will my Quest Laboratories Ltd IPO order be placed?

    Your Quest Laboratories Ltd IPO order will be placed on 15 May 2024.

  • What are the open and close dates of the Quest Laboratories Ltd IPO?

    The open and close dates of the Quest Laboratories Ltd IPO are 15 May 2024 to 17 May 2024.

  • What is the lot size and minimum order quantity of the Quest Laboratories Ltd IPO?

    The lot size and minimum order quantity of the Quest Laboratories Ltd IPO are 1200 and 1200 respectively.

  • What would be the listing gains on the Quest Laboratories Ltd IPO?

    The potential listing gains on the Quest Laboratories Ltd IPO will depend on various market factors and cannot be predicted with certainty.